IRIS
RIZZI, Rita
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.664
AS - Asia 4.862
EU - Europa 3.786
SA - Sud America 1.353
AF - Africa 187
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 9
Totale 20.872
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.520
SG - Singapore 2.132
CN - Cina 1.271
BR - Brasile 1.169
IT - Italia 857
HK - Hong Kong 727
SE - Svezia 668
RU - Federazione Russa 513
UA - Ucraina 443
DE - Germania 428
VN - Vietnam 308
FI - Finlandia 282
GB - Regno Unito 232
FR - Francia 126
IN - India 98
CI - Costa d'Avorio 94
CA - Canada 77
AR - Argentina 67
BD - Bangladesh 49
ID - Indonesia 49
MX - Messico 47
IE - Irlanda 45
PL - Polonia 37
ZA - Sudafrica 37
TR - Turchia 36
NL - Olanda 33
JP - Giappone 32
IQ - Iraq 30
EC - Ecuador 28
ES - Italia 27
BE - Belgio 24
CZ - Repubblica Ceca 21
CO - Colombia 20
VE - Venezuela 18
PY - Paraguay 16
PK - Pakistan 14
AT - Austria 13
CL - Cile 13
AE - Emirati Arabi Uniti 12
MA - Marocco 12
JO - Giordania 11
PE - Perù 11
UZ - Uzbekistan 11
AU - Australia 10
IR - Iran 10
EG - Egitto 9
LT - Lituania 9
SA - Arabia Saudita 9
KE - Kenya 8
KR - Corea 8
AZ - Azerbaigian 7
TN - Tunisia 7
ET - Etiopia 6
JM - Giamaica 6
KZ - Kazakistan 6
UY - Uruguay 6
EU - Europa 5
IL - Israele 5
NP - Nepal 5
TW - Taiwan 5
BO - Bolivia 4
BY - Bielorussia 4
GT - Guatemala 4
RO - Romania 4
SN - Senegal 4
XK - ???statistics.table.value.countryCode.XK??? 4
DO - Repubblica Dominicana 3
MD - Moldavia 3
MY - Malesia 3
OM - Oman 3
PH - Filippine 3
AL - Albania 2
AO - Angola 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
CH - Svizzera 2
GA - Gabon 2
HN - Honduras 2
KG - Kirghizistan 2
LK - Sri Lanka 2
TG - Togo 2
TH - Thailandia 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BH - Bahrain 1
BM - Bermuda 1
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
GI - Gibilterra 1
GY - Guiana 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LC - Santa Lucia 1
Totale 20.858
Salva come PNG Salva come JPEG
Città #
Singapore 1.107
Jacksonville 1.017
Chandler 1.011
Ashburn 949
Woodbridge 893
Fairfield 825
Hong Kong 708
Houston 525
Nyköping 470
Ann Arbor 454
Cambridge 431
Seattle 331
Beijing 313
Wilmington 297
Roxbury 256
Lawrence 241
Nanjing 239
New York 181
Boardman 172
Des Moines 161
Los Angeles 156
Dallas 145
Bari 142
Ho Chi Minh City 108
Inglewood 107
Abidjan 93
Princeton 89
São Paulo 85
Brooklyn 77
Shenyang 72
Buffalo 66
Hebei 66
Hanoi 64
Rome 61
Santa Clara 61
London 59
San Diego 55
Jiaxing 52
Dearborn 51
Florence 48
Nanchang 46
Munich 44
Dublin 43
Changsha 41
Milan 38
Moscow 38
Tianjin 37
Nuremberg 36
Paris 34
Guangzhou 33
Jakarta 32
Rio de Janeiro 31
Montreal 29
Helsinki 27
Council Bluffs 26
Pune 26
Tokyo 26
Turku 26
Warsaw 26
Belo Horizonte 24
Brasília 24
Phoenix 24
Brussels 23
Redwood City 22
Toronto 22
Johannesburg 21
Chennai 20
Chicago 20
Frankfurt am Main 20
San Francisco 20
Atlanta 19
Falkenstein 19
San Jose 19
Curitiba 18
Jinan 18
Washington 17
Denver 16
Noicattaro 16
Porto Alegre 15
Salvador 15
Shanghai 15
The Dalles 15
Campinas 14
Dhaka 14
Hefei 14
Kunming 14
Orem 14
Stockholm 14
Ankara 13
Manchester 13
Norwalk 13
Poplar 13
West Jordan 13
Wuhan 13
Augusta 12
Boston 12
Haiphong 12
Naples 12
New Delhi 12
Ningbo 12
Totale 13.553
Salva come PNG Salva come JPEG
Nome #
Leucemia linfatica cronica in trasformazione prolinfocitoide: descrizione di un caso 191
LIGHT/TNFSF14 as a new biomarker of bone disease in multiple myeloma patients experiencing therapeutic regimens 176
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese" 167
TRAIL effect on osteoclast formation in physiological and pathological conditions 151
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 150
A role of light as potential biomarker for progression of smoldering to symptomatic multiple myeloma 150
Non-treatment-related chronic myeloid leukemia as a second malignancy 145
Vascular Endothelial Growth Factor Serum Levels Are Elevated in Patients with Hereditary Hemorrhagic Telangiectasia 140
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients 137
Amyloid in bone marrow smears of patients affected by multiple myeloma 136
A case of AL amyloidosis associated with IgD multiple myeloma (MM): clinical and laboratory findings, and outcome 135
CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP) 135
Behçet's disease: an immune-mediated vasculitis involving vessels of all sizes 134
Alteration of the osteogenic properties of bone marrow stromal cells from multiple myeloma bone disease patients 133
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia 132
Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature 130
Sclerostin is overexpressed by plasma cells from multiple myeloma patients 127
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 127
Light/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. 126
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) 126
Autoimmune Myelofibrosis: report of three cases and review of the literature 122
ANALYSIS OF PROGNOSTIC FACTORS AND TIME TO FIRST TREATMENT IN YOUNG PATIENTS (<55 YEARS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE CENTER EXPERIENCE 120
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 119
Analysis of percent identity of IGHV mutation as prognostic factor in CLL patients treated with fludarabine, cyclofosfamide and rituximab: a single centre experience 117
A case of light chain (AL) amyloidosis associated with IgD Multiple Myeloma (MM): clinical features, laboratory findings and outcome 116
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 114
CD34CD2 Acute promyelocytic leukemia (APL): is this a distinct subset? 113
Anti-endothelial cell antibodies (AECA) in a patient wiyh Takayasu’s arteritis. In: Pathogenesis and immunotherapy of autoimmune diseases. Final program and abstract book 112
Rhabdomyolysis and acute tubular necrosis in coniine (hemlock)poisoning 112
Ibridizzazione in situ non isotopica. Attualità e prospettive 112
Another link between bone and immune system: LIGHT 111
Takayasu’s arteritis: a cell mediated large vessel vasculitis 111
Hepatitis C virus infection and mixed cryoglobulinemia: a striking association 111
Alteration of bone remodeling in multiple myeloma bone disease: role of sclerostin 110
A rare case of IgM-Multiple Myeloma 110
Altered osteogenic properties of bone marrow stromal cells from multiple myeloma patients 110
The role of multiparameter flow cytometry in the work-up of IGM-monoclonal gammopathies 109
A weekly infusion of bortezomib reduces peripheral neuropathy 109
Amyloidosis: clinical picture, immunological and biomolecular features, treatment prospects 108
Soluble Decoy Receptor 3 (DcR3) modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients 107
A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase 107
LIGHT/TNFSF14 Promotes Osteolytic Bone Metastases in Non-small Cell Lung Cancer Patients 107
In vitro osteoclastogenesis and T-cell RANKL expression in multiple myeloma-bone disease at diagnosis and in the setting of frontline treatment 106
Autoimmune hemolytic anemia during interferon-alfa therapy for chronic hepatitis C 106
Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients 106
Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion 105
A prospective randomized study comparing rituximab and dexamethasone vs dexamethasone alone in ITP: results of final analysis and long term follow up 105
REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA 105
DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION 104
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction 104
Acute tubular necrosis in the hemlock poisoning 103
The OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 103
Malignant lymphoma involving a Warthin’s tumor: a case with immunophenotypic and gene rearrangement analysis 101
Livelli sierici di VEGF in pazienti affetti da Sindrome di Rendu-Osler-Weber 101
Infection complications in patients with multiple myeloma treated with new drug combinations including thalidomide 101
DARA-VD VERSUS DARA-RD AS SALVAGE THERAPY FOR PATIENTS WITH MYELOMA. INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY RETE EMATOLOGICA PUGLIESE 101
The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 100
A phase II Study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: results of the first interim analysis 100
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia 99
The Role of LIGHT in Multiple Myeloma-Bone Disease 98
Myeloma cells suppress osteoblasts through sclerostin secretion 98
Alterazione delle capacità osteogeniche in cellule stromali ottenute da midollo osseo di pazienti affetti da mieloma multiplo 97
Immunogenicity of two idiotypes with a different immunoglobulin-chain distribution expressed on the same anti-CD4 Mab 97
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial 97
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 97
Bone marrow angiogenesis in autoimmune myelofibrosis 96
A phase II study of chlorambucil + rituximab (CLB-R) followed by R maintenance vs observation in elderly patients with previously untreated chronic lymphocytic leukemia (CLL): induction phase results 96
T cells support osteoclastogenesis in an in vitro model derived from psoritic arthritis 95
DCR3 involvement in multiple myeloma bone disease 94
T cells support the in vitro formation of osteoclasts in multiple myeloma-bone disease: the role of OPG/TRAIL interaction 94
Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience 94
LIGHT INVOLVEMENT IN MULTIPLE MYELOMA-OSTEOLYTIC BONE DISEASE 94
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 93
Anti-endothelial cell autoantibodies in patients with Behcet’s disease 93
Angiogenesis and hereditary hemorrhagic telangiectasia. Rendu-Osler-Weber disease 93
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 92
A Phase III study of enoxaparin versus aspirin versus low-dose warfarin as thrombophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide based-regimens 92
Irisin prevents trabecular bone damage and tumor invasion in a mouse model of multiple myeloma 92
Cost of illness in patients with multiple myeloma in Italy: the CoMiM study 91
P-ANCA atipici nelle malattie infiammatorie croniche intestinali 91
Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function 90
T cells support the osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease 89
L'AMILOIDOSI: QUADRI CLINICI, CARATTERISTICHE IMMUNOLOGICHE E BIOMOLECOLARI, PROSPETTIVE TERAPEUTICHE 89
Failure of an in vitro model of osteoclastogenesis in human plasma cell leukaemia (PCL) 88
Autoimmune bone marrow fibrosis: a distinct clinicopathological entity 87
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide 87
Aneurysms of the supra-aortic trunks in Takayasu's disease - Report of two cases 87
Clinical spectrum of accidental hemlock poisoning: neurotoxic manifestations, rhabdomyolysis and acute tubular necrosis 87
Schnitzler's syndrome: diagnosis, treatment, and follow-up. 87
The role of the Wnt-signaling antagonist Sclerostin in the development of osteolytic lesions in multiple myeloma 86
Circulating levels of cathepsin-k in multiple myeloma patients 86
Soluble CD4 antigen reactivity in intravenous immunoglobulin preparations: is it specific? 86
What Is New in the Treatment of Smoldering Multiple Myeloma? 86
Microvessel density and angiogenic cytokine expression in autoimmune myelofibrosis compared with chronic idiopathic myelofibrosis 85
Myeloma cells induce osteoblast suppression through sclerostin secretion 85
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. 85
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma 85
Kidney damage by ingestion of ethylene glicol 84
Economic and social burden of multiple myeloma in Italy – Co.Mi.M. Study 84
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma 84
Totale 10.776
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.587
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.587
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.148 0 0 0 0 0 101 234 126 204 242 151 90
2021/20221.790 78 253 7 128 56 77 73 96 126 79 314 503
2022/20232.648 380 231 111 271 344 375 41 300 495 16 45 39
2023/20241.332 200 212 73 66 97 238 65 69 8 55 101 148
2024/20254.078 114 55 403 140 110 366 310 344 182 187 622 1.245
2025/20264.376 1.181 365 575 970 859 426 0 0 0 0 0 0
Totale 21.209